<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818829</url>
  </required_header>
  <id_info>
    <org_study_id>13 038 07</org_study_id>
    <nct_id>NCT02818829</nct_id>
  </id_info>
  <brief_title>Biological and Clinical Database for Pancreatic Adenocarcinoma</brief_title>
  <acronym>BACAP</acronym>
  <official_title>Biological and Clinical Database for Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACAP is a biobank dedicated to the pancreatic adenocarcinoma funded by institut national&#xD;
      institue du cancer (INCa) and coordinated by Dr Barbara Bournet from Toulouse hospital. This&#xD;
      base includes clinical data and biological samples such as blood, serum, plasma, saliva, DNA&#xD;
      and RNA from tumors cells.&#xD;
&#xD;
      The mission of this prospective project is to make available to the scientific community a&#xD;
      clinical biological base from patients with pancreatic adenocarcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic cancer represents the fifth cause of death by cancer in Western countries. In over&#xD;
      90% of cases, it is due to an adenocarcinoma. The only curative treatment for pancreatic&#xD;
      cancer remains the surgical exeresis. This one can only be suggested as a curative treatment&#xD;
      in only 10 to 15% of cases. Besides, prevention or screening is impossible due to the absence&#xD;
      of clearly identified risk factors or groups and to the absence of useful markers for the&#xD;
      diagnosis in clinical practice.&#xD;
&#xD;
      The research efforts in this area must face a double challenge: saving time while improving&#xD;
      the diagnosis period and strengthen the therapeutic equipment. It is important to identify&#xD;
      and characterise the new molecular markers applicable for a better diagnosis and/or treatment&#xD;
      (especially the response factors to chemotherapy). The present project aims at creating a&#xD;
      multicentre national network used to set up a clinical biological base (CBB) dedicated to the&#xD;
      pancreatic adenocarcinoma, built on the best quality standards, for the biological resources&#xD;
      as well as the associated clinical and epidemiological data.&#xD;
&#xD;
      The originality of this CBB relies on the fact that it will have not only tumour tissues&#xD;
      sampled from surgical specimens of resectable tumours but also cell and biopsy material from&#xD;
      unresectable and/or metastatic tumours sampled under endoscopic ultrasonography (1500&#xD;
      biopsies over 3 years coupled to systematic blood samples). Endoscopic ultrasonography is a&#xD;
      technique used to specifically perform biopsies on pancreatic tumours and to obtain useful&#xD;
      cell material for research. To these samples will be associated every clinical and&#xD;
      epidemiological target data required for research projects related to this unique CBB in&#xD;
      France. From these samples, DNA and RNA will be especially isolated, as it is a precious&#xD;
      biological material for the programmed molecular analyses.&#xD;
&#xD;
      There are many stakes: creating a French network in order to form, with the prospective plans&#xD;
      over 3 years, a collection of tissue, biopsies, nucleic acids from pancreatic cancer&#xD;
      associated to circulating blood samples and relevant clinical data. Thanks to this&#xD;
      collection, the investigator team hope to be able to identify new molecular markers (from&#xD;
      cancer tissue and/or circulating blood from pancreatic cancer patients) applicable to&#xD;
      clinical practice to diagnose, to assess the prognosis or to predict the response to&#xD;
      pancreatic cancer chemotherapy. The investigator team will also try to identify new risk&#xD;
      factors for this cancer, especially regarding the diet. The base will thus be made up from 12&#xD;
      different French centres from University Hospital and private Centres where&#xD;
      gastroenterologists, oncologists, digestive surgeons, anatomopathologists, epidemiologists&#xD;
      intervene as they are all associated to scientific teams dedicated to pancreatic cancer,&#xD;
      itself already formed in collaborative networks.&#xD;
&#xD;
      Investigators hope through this project: to get a unique and exceptional CBB for pancreatic&#xD;
      cancer, to reach the required standards (especially Inca) for this CBB, and to be&#xD;
      internationally recognised. This base will be a strong guarantee to identify new molecular&#xD;
      markers for the diagnosis, the prognosis, and the predictive response to chemotherapy for&#xD;
      pancreatic cancer, especially when locally advanced. Finally, the epidemiological projects&#xD;
      related to this project are originally about the nutritional issues (regardless of the lipid&#xD;
      diet and the cachexia) associated to pancreatic cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Constitution of a transdisciplinary biobank with collection of biological samples with DNA</measure>
    <time_frame>Through the study completion, an average of 11 months</time_frame>
    <description>The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Constitution of a transdisciplinary biobank with collection of biological samples without DNA</measure>
    <time_frame>Through the study completion, an average of 11 months</time_frame>
    <description>The present project aims at creating, coordinating, animating a transdisciplinary multicentric national network, used to set up a clinical biological base (CBB) dedicated to the pancreatic adenocarcinoma</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <description>Collection of biological samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collection of biological samples</intervention_name>
    <description>Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsie,&#xD;
      tissue from tumor and adjacent tissue of pancreas&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a pancreatic adenocarcinoma proven cytologically or histologically without&#xD;
        any treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient eighteen years old&#xD;
&#xD;
          -  Histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
&#xD;
          -  Solid pancreatic mass explored with tomodensitometry or endoscopic ultrasonography&#xD;
             fine-needle aspiration&#xD;
&#xD;
          -  Informed consent signed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  no informed consent&#xD;
&#xD;
          -  pregnancy women&#xD;
&#xD;
          -  no histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barbara BOURNET, MD; PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara BOURNET, MD; PHD</last_name>
    <phone>5 61 32 32 35</phone>
    <phone_ext>+33</phone_ext>
    <email>bournet.b@chu-toulouse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cindy CANIVET, PHD</last_name>
    <phone>5 61 32 20 48</phone>
    <phone_ext>+33</phone_ext>
    <email>canivet.c@chu-toulouse.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique VENDRELY., MD</last_name>
      <email>veronique.vendrely@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaujon Hospital</name>
      <address>
        <city>Clichy La Garenne</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal HAMMEL, MD; PHD</last_name>
      <email>pascal.hammel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie TRUANT, MD; PHD</last_name>
      <email>Stephanie.TRUANT@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume PIESSEN, MD; PHD</last_name>
      <email>Guillaume.PIESSEN@CHRU-LILLE.FR</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre GUIBERT, MD</last_name>
      <email>Pierre.GUIBERT@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Private Hospital Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bertrand NAPOLEON</last_name>
      <email>bertrand.napoleon@dartybox.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François SEITZ, MD; PHD</last_name>
      <email>Jean-francois.SEITZ@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane GARCIA</last_name>
      <email>Stephane.GARCIA@ap-hm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Regional du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fréderic BIBEAU, MD; PHD</last_name>
      <email>Frederic.Bibeau@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric ASSENAT, MD, PHD</last_name>
      <email>e-assenat@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of NICE</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Geoffroy VANBIERVLIET, MD; PHD</last_name>
      <email>vanbiervliet.g@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint-Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique FARGE-BANCEL, MD, PHD</last_name>
      <email>dominique.farge-bancel@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinique du Trocadero</name>
      <address>
        <city>Paris</city>
        <zip>75016</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurent PALAZZO, MD</last_name>
      <email>laurent.palazzo@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pau Hospital</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe BERTHELEMY, MD</last_name>
      <email>philippe.berthelemy@ch-pau.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis BUSCAIL, MD; PHD</last_name>
      <email>buscail.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Yves SCOAZEC, MD; PHD</last_name>
      <email>Jean-yves.SCOAZEC@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.chu-toulouse.fr/-projet-bacap-</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>July 29, 2020</last_update_submitted>
  <last_update_submitted_qc>July 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adenocarcinoma</keyword>
  <keyword>Endoscopic ultrasonography</keyword>
  <keyword>Fine-needle aspiration</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Epidemiology</keyword>
  <keyword>DNA tumors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

